Hodgkin's lymphoma patients experience fatigue even after treatment
The study included data from 4,215 patients aged 18 to 60 years from first-line clinical trials for early-stage favourable (HD13 trial), early-stage unfavourable (HD14 trial), and advanced-stage (HD15 trial) Hodgkin’s lymphoma. The fatigue scale of the European Organization for Research and Treatment of Cancer QLQ-C30 questionnaire was used to evaluate fatigue from the time of diagnosis until 5 years after end of treatment.
Results showed a higher incidence of fatigue at baseline in patients with higher tumour burden at the time of diagnosis (mean fatigue score: 30.8 in HD13, 39.8 in HD14, 49.0 in HD15).
By the second year after the end of treatment, the mean fatigue scores were 28.5, 28.8 and 30.7 in HD13, HD14 and HD15, respectively. Five years after the end of treatment, fatigue scores were 30.8 in HD13, 27.1 in HD14, and 28.2 in HD15.
Baseline fatigue and age, but not treatment, predicted the incidence of fatigue during the second and fifth years after end of treatment. Patient sex and Hodgkin's lymphoma-specific risk factors at baseline were inconsistently associated with fatigue prognosis in the first, second and fifth years after treatment.
These results suggested that Hodgkin’s lymphoma patients experience acute and persistent fatigue, independent of disease stage and treatment. The experts recommended that intervention strategies can be developed to address fatigue in these patients.